scholarly journals Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer

2016 ◽  
Vol 161 (3) ◽  
pp. 453-461 ◽  
Author(s):  
Jason D. Robarge ◽  
Zereunesay Desta ◽  
Anne T. Nguyen ◽  
Lang Li ◽  
Daniel Hertz ◽  
...  
1989 ◽  
Vol 7 (1) ◽  
pp. 145-145
Author(s):  
James N. Ingle ◽  
Lloyd K. Everson ◽  
H. Sam Wieand ◽  
J. Kirk Martin ◽  
Henry J. Votava ◽  
...  

In Table 4 of the manuscript by Ingle et al published in the September issue (J Clin Oncol 6:1388–1396, 1988) an error was made in the dosage of tamoxifen. The planned dose should have read 140 mg/wk; the mean dose, 125 mg/wk; and the median dose, 140 mg/wk.


2007 ◽  
Vol 10 (1) ◽  
pp. 1-3 ◽  
Author(s):  
L. A. Schnaper ◽  
K. S. Hughes

Despite the fact that breast cancer is predominantly a disease of postmenopausal women, there have been no uniform recommendations for both locoregional and systemic therapy for women over 70. Until recently, older women have been excluded from clinical trials. This study is the first randomized trial that addresses the use of radiation therapy following lumpectomy in a favorable cohort of elderly women.


2004 ◽  
Vol 350 (11) ◽  
pp. 1081-1092 ◽  
Author(s):  
R. Charles Coombes ◽  
Emma Hall ◽  
Lorna J. Gibson ◽  
Robert Paridaens ◽  
Jacek Jassem ◽  
...  

The Breast ◽  
2010 ◽  
Vol 19 (5) ◽  
pp. 388-395 ◽  
Author(s):  
Kelly-Anne Phillips ◽  
Karin Ribi ◽  
Zhuoxin Sun ◽  
Alisa Stephens ◽  
Alastair Thompson ◽  
...  

2000 ◽  
Vol 55 (2) ◽  
pp. 100 ◽  
Author(s):  
Steven R. Cummings ◽  
Stephen Eckert ◽  
Kathryn A. Krueger ◽  
Deborah Grady ◽  
Trevor J. Powles ◽  
...  

2015 ◽  
Vol 9 (2) ◽  
pp. 142-148 ◽  
Author(s):  
Ana Maria López ◽  
Sandhya Pruthi ◽  
Judy C. Boughey ◽  
Marjorie Perloff ◽  
Chiu-Hsieh Hsu ◽  
...  

2004 ◽  
Vol 22 (9) ◽  
pp. 1605-1613 ◽  
Author(s):  
Anthony Howell ◽  
John F.R. Robertson ◽  
Paul Abram ◽  
Mikhail R. Lichinitser ◽  
Richard Elledge ◽  
...  

Purpose To evaluate the efficacy and tolerability of fulvestrant (Faslodex; AstraZeneca Pharmaceuticals LP, Wilmington, DE), a new estrogen receptor (ER) antagonist that downregulates ER and has no agonist effects, versus tamoxifen, an antiestrogen with agonist and antagonist effects, for the treatment of advanced breast cancer in postmenopausal women. Patients and Methods In this multicenter, double-blind, randomized trial, patients with metastatic/locally advanced breast cancer previously untreated for advanced disease were randomly assigned to receive either fulvestrant (250 mg, via intramuscular injection, once monthly; n = 313) or tamoxifen (20 mg, orally, once daily; n = 274). Patients' tumors were positive for ER (ER+) and/or progesterone receptor (PgR+), or had an unknown receptor status. Results At a median follow-up of 14.5 months, there was no significant difference between fulvestrant and tamoxifen for the primary end point of time to progression (TTP; median TTP, 6.8 months and 8.3 months, respectively; hazard ratio, 1.18; 95% CI, 0.98 to 1.44; P = .088). In a prospectively planned subset analysis of patients with known ER+ and/or PgR+ tumors (∼78%), median TTP was 8.2 months for fulvestrant and 8.3 months for tamoxifen (hazard ratio, 1.10; 95% CI, 0.89 to 1.36; P = .39). The objective response rate for the overall population was 31.6% with fulvestrant and 33.9% with tamoxifen, and 33.2% and 31.1%, respectively, in the known hormone receptor–positive subgroup. Both treatments were well tolerated. Conclusion In the overall population, between-group differences in efficacy end points favored tamoxifen, and statistical noninferiority of fulvestrant could not be demonstrated. However, in patients with hormone receptor–positive tumors, fulvestrant had similar efficacy to tamoxifen and was well tolerated.


Sign in / Sign up

Export Citation Format

Share Document